@Techinvestor
Re "The big question for the Board is to explain why this trial went ahead and was pumped up when they apparently knew the FDA would not recognise the primary endpoint!"
I've been reading back over the last few months/year to try to understand this ("the FDA would not recognise the primary endpoint") very issue.
I don't get the company strategy at all. Did the FDA not communicate this reality? Was the board hoping some other little miracle would pop up? I don't like the idea of a can just being booted down the road to sustain the SP, but I can draw no other conclusion when I look closely at this.
Baked out risks or raw prawns?
Tonight’s outcome, page-37
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |